Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Reader, Be Wary: Sponsors Keep Most 'Complete Response' Letter Content Under Wraps, FDA Says

Executive Summary

Agency analysis provides rare portrait of 'complete response' letters while adding to the case for increased transparency.


Related Content

Amgen's Reticence On Parsabiv Complete Response Letter Revives Transparency Issue
Talking It Out: Perseverance Helps Sponsors Overcome Disagreements With FDA
FDA Talking To Industry About Releasing “Complete Response” Letters